Nucleix’s Lung EpiCheck ® Liquid Biopsy Test Detects 85% of Early Stage Lung Cancers in High-Risk Smokers, Study Published in European Respiratory Journal
Nucleix, a liquid biopsy company revolutionizing cancer treatment by detecting the disease earlier, today announced a publication showing its Lung EpiCheck® test detected 85% of early stage lung cancers among individuals at high risk for developing the disease based on their history of smoking. The study, entitled “Validation of Lung EpiCheck®, a novel methylation-based blood assay, for the detection of lung cancer in European and Chinese high-risk individuals,” was published online today ahead of print in the European Respiratory Journal (ERJ).
Lung EpiCheck analyzed 728 different samples in the study, including 311 from individuals with varying stages of lung cancer and 417 matched controls. By adjusting measurement of six methylation markers found in blood, the test was tailored to meet the needs of specific patient populations: increased sensitivity for high-risk populations, or increased specificity for low-risk populations. When focused on increased sensitivity for a high-risk population of past and current smokers, Lung EpiCheck demonstrated an overall sensitivity of 87% detection of lung cancer across all stages, 85% detection of Stages I-IIIA non-small cell lung cancer (NSCLC) and 78% detection of Stage I NSCLC, each with a specificity of 64%. The test also detected 100% of small cell lung cancer, a rapidly growing and deadly cancer that is typically challenging to detect. When focused on increased specificity for a low-risk population, Lung EpiCheck demonstrated overall specificity of 91% and sensitivity of 74%. Combining Lung EpiCheck with established risk factors improved the AUC, the ability to distinguish between patients with and without disease, from 88% to 94%.
“In the United States, very few high-risk individuals follow the recommended screening guidelines of annual, low-dose CT scans. Offering a highly sensitive test to those who decline to undergo the recommended scan gives them a better chance for early detection, while a false positive would simply result in proceeding to the current standard of care,” said Chris Hibberd, chief executive officer of Nucleix. “We are taking steps to further advance Lung EpiCheck as a low-cost blood test to encourage more patients to comply with recommended screening.”
Lung cancer is the deadliest cancer, with 1.76 million deaths worldwide in 2018.1 Survival hinges on early detection, with 5-year survival rates nearly 10 times greater for Stage I cancer than Stage IV cancer.2 The U.S. Preventive Services Task Force recommends annual screening with low-dose computed tomography (also called a low-dose CT scan, or LDCT) for current and past smokers at the highest risk of developing lung cancer – specifically, those individuals age 55-80 who have smoked an average of one pack of cigarettes a day for more than 30 years and currently smoke, or who quit, within the past 15 years.3 Even though there is no cost to these individuals to receive a LDCT scan, and it has been shown to improve survival,4 only 7%5 to 14%6 of those eligible in the United States follow this guideline due to a combination of inconvenience, missing infrastructure and fear of radiation exposure.
“Lung cancer is most often diagnosed at late stages when chances of cure are limited,” said Prof. Mina Gaga, Director and Head, 7th Respiratory Medicine Department, Athens Chest Hospital and the principal investigator of the study. “Tests for early diagnosis are urgently needed and the Lung EpiCheck data published in the ERJ show important promise for the implementation of lung cancer screening.”
Nucleix is continuing to optimize the Lung EpiCheck test and is advancing development of next-generation versions, with a goal of making a test available within 1 to 2 years.
About Lung EpiCheck®
Lung EpiCheck is designed to provide a simple blood test to detect lung cancer at its earliest stages. The test utilizes PCR-based technology for a low-cost analysis of subtle, disease-specific changes in DNA methylation markers. Lung EpiCheck is being developed for potential use in individuals with a history of smoking who are at high-risk of developing lung cancer, and do not comply with the guidelines for annual screening with LDCT scans. The test is not yet commercially available.
Nucleix is a liquid biopsy company revolutionizing cancer treatment with earlier disease detection at a time when intervention can bring the greatest impact for patients. Leveraging PCR-based epigenetics, the Company’s pioneering testing approach uses methylation-based identification for early-stage and recurring cancer detection. The Company’s non-invasive EpiCheck® platform delivers highly accurate and sensitive results, all while providing a seamless testing option for patients and the healthcare system. The Company is building an EpiCheck franchise, beginning with the Bladder EpiCheck testing kit, marketed in Europe for bladder cancer recurrence. The Company is advancing a Lung EpiCheck test toward commercialization for high-risk individuals, while advancing additional tests for high-risk diseases. For more information, please visit: https://www.nucleix.com.
1 GLOBOCAN2018 Global Cancer Observatory http://gco.iarc.fr.
2 Lung cancer Stat Facts: Lung and Bronchus Cancer. https://seer.cancer.gov/statfacts/html/lungb.html entered October 2020.
4 NEJM Research team. Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening. N Engl J Med 2011;365:395-409.
5 LCSR Available Facility Reports. (n.d.). Retrieved October 28, 2020, from https://nrdrsupport.acr.org/support/solutions/articles/11000039783-lcsr-available-reports
6 Zahnd WE, Eberth JM. Lung cancer screening utilization: A behavioral risk factor surveillance system analysis. Am J Prev Med. 2019;57:250-255. doi: 10.1016/j.amepre.2019.03.015.
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Citi Private Bank Issues Outlook 2021: The New Economic Cycle: Investing for a Post-COVID World4.12.2020 17:36:00 CET | Press release
Citi Private Bank has released its Outlook 2021: The New Economic Cycle: Investing for a Post-COVID World. The twice-yearly publication provides in-depth insights into the global economy and financial markets for the coming year and highlights multi-year “unstoppable trends” for client portfolios. This edition outlines why this is a remarkable time to be an investor. Just as the pandemic changed the price of every security when it arrived, the departure of COVID will mark the beginning of a new economic cycle, creating new opportunities for investors. Citi Private Bank expects 2021 will benefit from an economy that demonstrated resilience in the face of the worst global healthcare crisis in more than a century. 2020 was an opportunity for the world to “test drive the future” and make way for growth as the pandemic ebbs. The tailwinds for 2021 are underappreciated: our financial system is strong, government actions to protect individuals and businesses have been effective, technological
Takashi Nagao Appointed President and Chief Executive Officer of Medicago4.12.2020 17:00:00 CET | Press release
Medicago, a biopharmaceutical company headquartered in Quebec City, Canada, today announced Takashi Nagao as the company’s new President and Chief Executive Officer. Prior to becoming President and CEO, Mr. Nagao served as the Chairman of the Board of Medicago, where for the last four years, he has guided Medicago executives to get the company to where it is today. Medicago, a research and development company for the last 20 years, is embarking on a transformative year, one that will see the company build on its R&D roots to become a company that also produces and commercializes vaccines and other immunotherapies. Mr. Nagao has extensive experience leading pharmaceutical companies through the pre-commercial and commercial process and is well positioned to ensure the successful launch of Medicago’s COVID-19 and influenza vaccines, subject to regulatory approvals. Mr. Nagao will continue Medicago’s evolution towards its goal of being a fully operational commercial entity, able to respond
WorldRemit Leads the Way Offering a USD Payout Option in Nigeria4.12.2020 16:46:00 CET | Press release
WorldRemit, a leading digital cross-border payments business has announced that its customers in Nigeria can now receive remittances in foreign currency (USD) through its cash pick up providers. Following the announcement of the Central Bank of Nigeria (CBN) a day before, WorldRemit quickly adapted to the new requirements making it the first digital service to offer its customers worldwide the option of cash pickup in USD in Nigeria. WorldRemit enables Nigerians in over 50 countries around the world to support their family and friends in Nigeria. The decision by the Central Bank of Nigeria (CBN) to allow international money transfers to be paid in foreign currency, is aimed at providing increased liquidity in the foreign exchange market. The bank explained that the new regulation is part of its efforts to liberalize, simplify and improve the receipt and administration of diaspora remittances into Nigeria. Gbenga Okejimi, Country Manager, Nigeria and Ghana, at WorldRemit, said:“ We are
PPC Upgraded to ‘B’ with ‘Stable’ Outlook by S&P4.12.2020 15:16:00 CET | Press release
In its annual research update released on 27 November 2020, S&P upgraded PPC’s stand-alone credit profile (SACP) upward by two notches to ‘B’ from ‘CCC+’, resulting in an overall upgrade of the long-term credit rating of PPC to ‘B’ from ‘B-‘. According to S&P the two notch upgrade in PPC’s standalone corporate rating confirms that the Company’s strategic repositioning and the improved Greek energy market fundamentals have transformed its competitive position, reducing past concerns over its liquidity and long-term sustainability. The ‘Stable’ outlook underscores S&P’s expectation that PPC will continue to deliver on its transformation plan, with solid liquidity and improved margins. PPC’s strategic plan to convert its generation mix toward lower carbon dioxide (CO2) emissions improve its fleet competitiveness and long-term prospects. As mentioned in their report, S&P expects a substantial increase in EBITDA and improvement in credit metrics on the back of higher profitability as PPC ac
Chengdu Launches Online Exhibition of History and Culture to Enhance Cultural Ties With European Countries4.12.2020 13:17:00 CET | Press release
The launching ceremony of Chengdu History and Culture Overseas Virtual Exhibition was held by the Chengdu Chronicles Compilation Committee at Chengdu Chronicles Office on 24 November. The event, along with the unveiling ceremony of Chengdu Chronicles Culture Overseas (Europe) Exchange Cooperation, were witnessed by distinguished guests in many European countries including the Netherlands, Germany and Belgium through video and online connections. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201204005278/en/ On November 24, Gao Zhigang (center), Director of Chengdu Chronicles Compilation Committee at Chengdu Chronicles Office, and other guests attend the launching ceremony of Chengdu History and Culture Overseas Virtual Exhibition. (Photo: Business Wire) Chengdu History and Culture Overseas Virtual Exhibition will also be launched at major foreign media platforms for audiences all over the world. Gao ZhiGang, Director of Che
New Phase 3 Data Show TAK-620 (maribavir), an Investigational Drug for the Treatment of Transplant Recipients with Refractory/Resistant Cytomegalovirus (CMV) Infections, Meets Primary Endpoint4.12.2020 12:00:00 CET | Press release
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced top-line results from the Phase 3 clinical trial evaluating the efficacy and safety of the investigational drug TAK-620 (maribavir), in the treatment of transplant recipients with refractory/resistant cytomegalovirus (CMV) infection. The TAK-620-303 (SOLSTICE) trial (NCT02931539) is a multicenter, randomized, open-label, active-controlled trial comparing eight weeks of treatment with either maribavir or investigator assigned treatment (IAT) in transplant recipients with CMV infection refractory or resistant to existing antiviral treatments (i.e., one or a combination of ganciclovir, valganciclovir, foscarnet or cidofovir). The SOLSTICE trial met its primary endpoint, defined as the proportion of patients who achieved confirmed CMV viremia clearance compared to IAT at the end of Study week 8. In addition, the SOLSTICE trial met its key secondary endpoint, defined as achievement of CMV viremia clearance
Janssen Submits Marketing Authorisation Extension to the European Medicines Agency to Register Paliperidone Palmitate 6-Monthly (PP6M) for Treatment of Schizophrenia in Adults4.12.2020 10:01:00 CET | Press release
The Janssen Pharmaceutical Companies of Johnson & Johnson submitted a Marketing Authorisation Extension Application to the European Medicines Agency (EMA) to register paliperidone palmitate 6-monthly (PP6M) for the maintenance treatment of schizophrenia in adult patients who are clinically stable on paliperidone palmitate 1‑monthly (PP1M)1 or 3-monthly (PP3M)2 injectable products. If approved, this long‑acting injectable will provide adults living with schizophrenia a twice-yearly dosing regimen, the longest dosing interval available for an antipsychotic medication in the European Economic Area.3 “Janssen’s roots in neuroscience began with research and development of novel therapeutic options for schizophrenia, and this filing builds on that 60-year commitment,” said Bill Martin, Global Therapeutic Area Head, Neuroscience, Janssen Research & Development, LLC. “We designed this unique dosing regimen so people with schizophrenia and their healthcare team can focus less on medication inte
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom